N4 Pharma PLC (AIM: N4P) has officially changed its name to Thalia Therapeutics plc, effective March 18, 2026.
Alongside the rebrand, the company’s ticker on the London Stock Exchange has changed from N4P to THAT.
The new name reflects the company’s strategic shift toward becoming a therapeutics-focused biotechnology business, centred on advancing treatments for cancer and other diseases using its Nuvec® gene delivery platform.
The company confirmed that existing share certificates remain valid, and the name change will have no impact on shareholders’ holdings.
The Company further announces that the change of name has now taken effect following registration at Companies House and will become effective on the London Stock Exchange tomorrow, 18 March 2026.
The Company’s TIDM will change from N4P to THAT. The Company’s LEI (213800OIN8T68PM7HK77), ISIN (GB00BYW8QM32) and SEDOL (BYW8QM3) will remain unchanged.
Shareholders should note that their holdings of ordinary shares in the Company will not be affected by the change of name. Existing share certificates should be retained as they remain valid for all purposes and new share certificates will not be issued.
Pursuant to AIM Rule 26, the proxy votes received in relation to the resolution will be made available on the Company’s website, and the Company’s website will be updated from tomorrow at https://www.thaliatx.com
Dr David Solomon, Chief Executive Officer of Thalia Therapeutics, commented:
“The change of name to Thalia Therapeutics reflects our strategic evolution into a therapeutics-focused biotechnology company. With a growing RNA therapeutics pipeline and our proprietary Nuvec® delivery platform, we believe the Company is well positioned to advance innovative treatments and deliver long-term value for shareholders.”
